COMPANY PROFILE

Hemanext

Explore full profile

A medical technology company

Lexington, United StatesFounded 2004Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Hemanext

Hemanext is a global biomedical technology pioneer specializing in transfusion medicine. The company focuses on enhancing the quality, functionality, and viability of stored red blood cells (RBCs) to improve patient outcomes. Hemanext operates in the healthcare sector, primarily serving hospitals, blood banks, and medical research institutions. The company's business model revolves around the research, development, and commercialization of advanced storage solutions for RBCs. Revenue is generated through the sale of these specialized storage systems and related technologies. By addressing the challenges associated with RBC storage, such as donor variability and oxygen levels, Hemanext aims to set new standards in transfusion medicine. The company is committed to delivering innovations that optimize the therapeutic impact of blood transfusions, thereby adding value to the healthcare system.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2004
Headquarters: Lexington, United States
Employees: 36
Open positions: 1
Dealroom signal: 82.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Oct 2025	$0	—	National Institutes of Health	↗
SERIES BOther financing	Jul 2025	$19M	$172M	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Hemanext website traffic

Latest recorded traffic for Hemanext is 1.8K monthly website visits, down 43.8% over the last three months. Hemanext's team grew 0% over the past year.

Latest monthly visits1.8K 3-month web change-43.8% 1-year team growth0%

Monthly website visitsJan 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Executive AssistantRaleigh, NC · Human Resources · Jul 16, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XBxCystence BioTherapeutics for Polycystic Kidney Disease treatment	District of Tuggeranong, Australia	Operational	3	$485K	—
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
AIAiberRemote medical support technology for aviation and maritime	Winshill, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
NENeomorphDeveloping novel drugs targeting previously untreatable disease-causing proteins using molecular degradation technology	San Diego, United States	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
GEGelmetixInjectable polymer gel for non-surgical chronic pain treatment	London, United Kingdom	Operational